Nucleotide RT inhibitors

A similar group of drugs are called nucleotide reverse transcriptase inhibitors (NtRTIs), or nucleotide analogues. These drugs differ from NRTIs in that they require only one phosphorylation step within a cell. Since they persist longer in cells, they can be taken less often. There is currently only one licensed NtRTI and none are presently in clinical trials:

  • TDF  tenofovir (Viread)

For further information on this NtRTI, see A to Z of antiretroviral drugs.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.